<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To investigate t(14;18)/IGH-BCL2 in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) cases from Taiwan </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: We retrospectively studied 93 consecutive cases, using immunohistochemistry and fluorescence in-situ hybridization (FISH) </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-nine (63%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were low-grade (LG) and 34 (37%) were high-grade (HG; 24% FL3A and 13% FL3B) </plain></SENT>
<SENT sid="3" pm="."><plain>FISH showed IGH, BCL2 and BCL6 rearrangements in 59%, 47% and 11% of cases, respectively, and MYC rearrangement in 5% of FL3A <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and 25% of FL3B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The translocation partner of <z:hpo ids='HP_0000001'>all</z:hpo> BCL2 rearrangements was IGH, with IGH-BCL2 fusion in 63% of LG <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and 18% of HG <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>LG <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were enriched with a CD10+/bcl-2+/MUM1- phenotype, and were frequently associated with BCL2 rearrangement but less commonly with BCL6 rearrangement </plain></SENT>
<SENT sid="6" pm="."><plain>FL3A <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were more closely related to FL3B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> than to LG <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> in immunophenotype and genetic aberrations </plain></SENT>
<SENT sid="7" pm="."><plain>There was no statistically significant difference between grade 1 and two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, between FL3A and FL3B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> or between nodal and extranodal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> in immunophenotypic or FISH findings </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative survival rate was higher in LG FL patients with IGH-BCL2 translocation than in those without rearrangement </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In Taiwan, FL3A <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were more closely related to FL3B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> than to LG <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, and a literature review showed that the frequency of t(14;18)/IGH-BCL2 in FL in Taiwan is among the lowest in the world </plain></SENT>
</text></document>